TGFB1 and cancer: Based on the fact that TGF-β is the dominant inhibitory pathway, the dual blockade of TGF-β and PD-1/PD-L1 by YM101 could effectively alter the ‘cancer-immunity set point,’ converting immune tolerance to activated T cell-immunity.